



SPANISH NATIONAL CANCER RESEARCH CENTRE

CNIO FRONTIERS MEETINGS 2015

Madrid 22–25 March 2015

NEW TRENDS IN ANTICANCER DRUG DEVELOPMENT

Application deadline **February 23rd**

Organisers

MANUEL HIDALGO

CNIO, Madrid, Spain

ALBERTO BARDELLI

IRCC, Torino, Italy

LILLIAN SIU

Princess Margaret Cancer Centre, Toronto, Canada

JOSEP TABERNERO

VHIO, Barcelona, Spain

Key Note Lectures

DREW PARDOLL

Johns Hopkins University, Baltimore, USA

WILLIAM PAO

Roche Pharma Research & Early Development, Basel, Switzerland

TAK W. MAK

Ontario Cancer Institute, Toronto, Canada

Confirmed speakers

ALEX ADJEI

Rosewell Park Cancer Institute, Buffalo, USA

GERHARDT ATTARD

ICR, London, UK

MARIANO BARBACID

CNIO, Madrid, Spain

ALBERTO BARDELLI

Institute for Cancer Research of Candiolo, Torino, Italy

HILARY CALVERT

UCL, London, UK

LUIS DIAZ

Johns Hopkins University, Baltimore, USA

JEFFREI A. ENGELMAN

Massachusetts General Hospital Cancer Center, USA

MANEL ESTELLER

IDIBELL, Barcelona, Spain

OSCAR FERNÁNDEZ-CAPETILLO

CNIO, Madrid, Spain

CARLOS GARCÍA-ECHEVERRÍA

Sanofi, Paris, France

MANUEL HIDALGO

CNIO, Madrid, Spain

SUNIL R HINGORANI

Fred Hutchinson Cancer Research Center, Seattle, USA

ANTONIO JIMENO

University of Colorado Cancer Center & Charles C. Gates Center of Stem Cells Biology, Aurora, USA

IGNACIO MELERO

CIMA and Clínica Universidad de Navarra, Pamplona, Spain

DAVID J. SHIELDS

Pfizer Pharmaceuticals, La Jolla, USA

LILLIAN SIU

Princess Margaret Cancer Centre, Toronto, Canada

MARIO SZNOL

Yale University, New Haven, USA

JOSEP TABERNERO

VHIO, Barcelona, Spain

CHRISTOPHE LE TOURNEAU

Curie Institute, Paris, France

JAAP VERWEIJ

Erasmus University Medical Centre, Rotterdam, The Netherlands

ELISABETH G. DE VRIES

University Med. Ctr., Groningen, The Netherlands

ANN L. WHITE

University of Southampton, UK



For further information and to apply please go to www.cnio.es/events
Centro Nacional de Investigaciones Oncológicas (CNIO).
Melchor Fernández Almagro 3, 28029 Madrid



Centro Nacional de Investigaciones Oncológicas



Madrid 22–25 March 2015

NEW TRENDS IN ANTICANCER DRUG DEVELOPMENT

Application deadline **February 23rd**



CNIO Frontiers Meeting New Trends in Anticancer Drug Development March 22-25, 2015

Venue: Spanish National Cancer Research Centre (CNIO) Auditorium

Chairpersons:

Manuel Hidalgo, CNIO, Madrid, Spain

Josep Taberner, VHIO, Barcelona, Spain

Alberto Bardelli, ICR, Torino, Italy

Lillian Siu, Princess Margaret Cancer Centre, Toronto, Canada

Rationale:

During the last few years there has been continued progress in new anticancer drug development. New agents ranging from small molecules to engineered antibodies to immune modulators have been approved for cancer treatment. Furthermore, a large portfolio of new agents is currently at different stages of development. New cancer drug development has evolved methodologically from a one-size fits all approach to a personalize development mode. New drugs are targeted to specific new cancer abnormalities and clinical development is geared to selecting patients with these specific abnormalities. In addition to new clinical trial designs, there has been significant interest in strategies for non-invasive disease monitoring such as assessment of liquid biopsies or circulating tumor cells as well as in implementing preclinical models in the so called co-clinical trials approach. Since 2010 when we organized a CFM in Molecular Cancer Therapeutics there has been substantial new progress for a new meeting on the topic.

Sunday March 22nd

20:00-22:00

Welcome cocktail for Speakers & Participants

Venue: Don Pio Hotel (Av. Pío XII, 25 - 28016 Madrid, Spain)

<http://www.hoteldonpio.com/en>



Monday March 23rd

- 08:45-09:00** **Opening Remarks**
Josep Taberero, VHIO, Barcelona, Spain
Alberto Bardelli, ICR, Torino, Italy
- 09:00-09:45** **Key Note Lecture # 1**
Chairperson: Jesus Garcia Foncillas, FJD, Madrid, Spain
- Targeted Therapies: Patient Selection and Mechanisms of Resistance**
William Pao, Roche Pharma Research & Early Development, Basel, Switzerland
- 09:45-12:15** **New Targets-Pathways in Clinical Development (1)**
Chairperson: Emiliano Calvo, CIOCC, Madrid, Spain
- 09:45-10:15 Androgen Receptor Blockade
Gerhardt Attard, ICR, London, UK
- 10:15-10:45 PI3K/mTOR Inhibitors
Josep Taberero, VHIO, Barcelona, Spain
- 10:45-11:15** **Coffee Break & Group Picture**
- 11:15-11:45 Title tba
Jeffrei A. Engelman, Massachusetts General Hospital Cancer Center, USA
- 11:45-12:15 Ras-Raf-MEK Inhibitors
Alex Adjei, Roswell Park Cancer Institute, Buffalo, USA
- 12:15-12:45 Title tba
David J. Shields, Pfizer Pharmaceuticals, La Jolla, USA
- 12:45-13:45** **Lunch Break**
- 13:45-15:45** **Innovative Approaches in Drug Development**
Chairperson: Eduardo Díaz-Rubio, San Carlos University Hospital, Madrid, Spain
- 13:45-14:15 Establishing dose, schedule and population(s): Novel trial approaches
Jaap Verweij, Erasmus Univ. Med. Ctr., Rotterdam, The Netherlands
- 14:15-14:45 Precision medicine for cancer patients
Alberto Bardelli, ICR, Torino, Italy
- 14:45-15:15 Co-Clinical Trial Strategies
Mariano Barbacid, CNIO, Madrid, Spain
- 15:15-15:45 Incorporating Novel Imaging Methods in Early Drug Development
Elisabeth G. de Vries, University Med. Ctr., Groningen, The Netherlands



Keynote Lectures: 40'+5' discussion
Talks: 25'+5' discussion
Short Talks: 10'+5' discussion

15:45-16:15 **Coffee Break**

16:15-17:00 **Short Talks**

Three 15 min talks from submitted abstracts

Tuesday March 24th

09:00-09:45

Key Note Lecture # 2

Chairperson: Alfredo Carrato, Hospital Ramon y Cajal, Madrid, Spain

Harnessing the Immune System to Treat Cancer

Drew Pardoll, Johns Hopkins University, Baltimore, USA

09:45-12:45

New Targets-Pathways in Clinical Development (2)

Chairperson: David Olmos, CNIO, Madrid, Spain

09:45-10:15 Targeting DNA Damage Repair Pathways
Hilary Calvert, UCL, London, UK

10:15-10:45 Antibody-drug conjugates – a new wave of targeted cancer drugs
Carlos García-Echeverria, Sanofi, Paris, France

10:45-11:15

Coffee Break

11:15-11:45 Targeting the Epigenome
Manel Esteller, IDIBELL, Barcelona, Spain

11:45-12:15 Stromal Disrupting Strategies
Sunil R Hingorani, Fred Hutchinson Cancer Research Center, Seattle, USA

12:15-12:45 Developmental and Cancer Stem Cells Pathway Inhibitors
Antonio Jimeno, University Of Colorado Cancer Center & Charles C. Gates Center of Stem Cells Biology, Aurora, USA

12:45-13:45

Lunch Break

13:45-15:45

Immunotherapy Approaches for Cancer Treatment

Chairperson: Jesús García-Donas, Sanchinarro Univ. Hospital, Madrid, Spain

13:45-14:15 Check-point Inhibitors and Vaccine Combinations
Mario Sznol, Yale University, New Heaven, USA

14:15-14:45 From mechanisms to combinations in novel cancer immunotherapies
Ignacio Melero, CIMA & Clinica Universidad de Navarra. Pamplona. Spain



Keynote Lectures: 40'+5' discussion
Talks: 25'+5' discussion
Short Talks: 10'+5' discussion

14:45-15:15 Targeting oncogene-induced DNA damage for cancer therapy
Oscar Fernández Capetillo, CNIO, Madrid, Spain

15:15-15:45 Agonistic CD 40 Antibodies and Immune Therapy
Ann L. White, University of Southampton, UK

15:45: 16:15 Coffee Break

16:15-17:00 Short Talks

Three 15 min talks from submitted abstracts

Wednesday March 25th

09:00-09:45 Key Note Lecture # 3
Chairperson: Miguel Quintela, CNIO, Madrid, Spain

Exploiting Cancer Metabolic Vulnerabilities
Tak W. Mak, Ontario Cancer Institute, Toronto, Canada

09:45-11:45 Personalizing Cancer Treatment
Chairperson: Fatima Al-Shahrour, CNIO, Madrid, Spain

9:45-10:15 Novel Applications of Cancer Genomics to Personalized Medicine
Luis Diaz, Johns Hopkins University, Baltimore, USA

10:15-10:45 Designing Clinical Trials for Personalize Medicine
Lillian Siu, Princess Margaret Cancer Centre, Toronto

10:45-11:15 Worldwide Initiatives in Personalize Medicine
Christophe Le Tourneau, Curie Institute, Paris, France

11:15-11.45 Integrating PDX Models in Personalize Medicine Studies
Manuel Hidalgo, CNIO, Madrid, Spain

11:45-12:00 Closing Remarks
Manuel Hidalgo, CNIO, Madrid, Spain
Lillian Siu, Princess Margaret Cancer Center, Toronto, Canada



Keynote Lectures: 40'+5' discussion
Talks: 25'+5' discussion
Short Talks: 10'+5' discussion